Full Breakdown
In-Utero Stem Cell Therapy Shows Promise for Spina Bifida Treatment
2/27/2026, 9:23:12 AM
Groundbreaking Clinical Trial Findings
A recent clinical trial has demonstrated that administering stem cells to unborn babies diagnosed with myelomeningocele, the most severe form of spina bifida, during in-utero surgery is both safe and potentially transformative. Conducted by researchers at the University of California, Davis, the trial involved six fetuses who received placenta-derived mesenchymal stem cells (PMSCs) applied directly to their exposed spinal cords during corrective surgery. The study, published in *The Lancet*, indicates that this innovative approach not only preserved the integrity of the surgical repair but also reversed hindbrain herniation, a common complication associated with spina bifida.
Details of the Procedure
The trial, which took place from June 2021 to December 2022, involved a low transverse laparotomy to expose the uterus, followed by a hysterotomy to access the fetus. The PMSCs were applied topically to the spinal cord after the neural placode was dissected. All six infants were born without complications, and postnatal MRI scans confirmed the absence of cerebrospinal fluid leaks, infections, or abnormal tissue growth. The infants were delivered at a median gestational age of 34 weeks and showed no serious adverse effects attributable to the stem cell treatment.
Implications for Future Treatments
Dr. Diana Farmer, who led the study, expressed optimism about the potential of this therapy to become standard practice for treating spina bifida. She noted, “If it makes more children able to walk who wouldn’t have then it would become their standard of care.” The results suggest that this combined approach of fetal surgery and stem cell therapy could significantly improve mobility and quality of life for affected children.
Criticism & Caution
Despite the promising results, experts urge caution. Dr. Eyal Krispin from Boston Children's Hospital highlighted the need for further research to assess long-term risks, including potential complications such as tethered cord or spinal cysts. The current study's small sample size necessitates additional large-scale trials to confirm the efficacy and safety of the treatment. Dr. Shamshirsaz emphasized that while the findings are encouraging, they represent only the initial steps in a much larger journey toward establishing this therapy as a standard option.
Official Statements & Responses
Kate Steele, chief executive of the charity Shine, remarked on the significance of the trial, stating, “The advances in stem cell science that have enabled this first-in-human trial to be possible are remarkable.” She expressed hope that this therapy could lead to improved outcomes for children with spina bifida.
What's Next
The researchers plan to conduct further studies to evaluate the long-term safety and efficacy of PMSCs in improving motor function and bowel and bladder control. These upcoming trials aim to solidify the role of stem cell therapy in fetal surgery and potentially expand its application to other congenital conditions.
Verbatim Quotes
- “If it makes more children able to walk who wouldn’t have then it would become their standard of care,” — Dr. Diana Farmer, Lead Researcher
- “The advances in stem cell science that have enabled this first-in-human trial to be possible are remarkable and we are delighted …” — Kate Steele, Chief Executive of Shine
- “The next step would be to show that it's really beneficial, and then how applicable this is to different surgical approaches,” — Dr. Eyal Krispin, Boston Children's Hospital
This trial marks a significant milestone in the treatment of spina bifida, paving the way for future advancements in fetal surgery and stem cell applications.
